Leishmaniasis: all 185 studies
Page 2 of 2. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.
- Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult VolunteersCompletedNCT02071758Phase 1
- Liposomal Amphotericin in Disseminated LeishmaniasisCompletedNCT02025491Phase 3
- Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients.CompletedNCT02011958Phase 3
- WR 279,396 for the Treatment of Cutaneous LeishmaniasisCompletedNCT01988909Phase 2
- Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in SudanTerminatedNCT01980199Phase 2
- A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)CompletedNCT01975051Phase 4
- High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and ManausTerminatedNCT01953744Phase 3
- The Healthcare Professionals and the LeishmaniasisCompletedNCT01896362
- Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in ColombiaCompletedNCT01845727Phase 1/2
- Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)CompletedNCT01766830Not applicable
- LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE VaccineCompletedNCT01751048Phase 1
- Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in IndiaCompletedNCT01661296Phase 4
- Replacement of Insecticides to Control Visceral Leishmaniasis (VL)CompletedNCT01644682Phase 3
- Paromomycin for Individuals With Uncomplicated Cutaneous LeishmaniasisNo longer availableNCT01641796
- Single Dose Liposomal Amphotericin B for Visceral LeishmaniasisStatus unknownNCT01566552Phase 4
- Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult VolunteersCompletedNCT01484548Phase 1
- Add-on Study of Pentoxifylline in Cutaneous LeishmaniasisCompletedNCT01464242Phase 2/3
- Pharmacokinetics of Miltefosine in Children and AdultsCompletedNCT01462500Phase 4
- SCH708980 With and Without AmBisome for Visceral LeishmaniasisWithdrawnNCT01437020Phase 1/2
- Antimony Plus Pentoxifylline in Cutaneous LeishmaniasisCompletedNCT01381055Phase 2/3
- Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous LeishmaniasisCompletedNCT01380314Phase 2
- Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and AntimonyTerminatedNCT01380301Phase 2
- Clinical Trial of Miltefosine to Treat Mucosal LeishmaniasisCompletedNCT01377974Phase 2
- An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in BangladeshCompletedNCT01328457Not applicable
- Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in BrazilTerminatedNCT01310738Phase 4
- Low Antimonial Dosage in American Mucosal LeishmaniasisStatus unknownNCT01301937Phase 2/3
- Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous LeishmaniasisCompletedNCT01301924Phase 2/3
- Intralesional Antimony for Bolivian Cutaneous LeishmaniasisCompletedNCT01300975Phase 2
- A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in BangladeshCompletedNCT01240473Not applicable
- Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-AcetylcysteineStatus unknownNCT01138956Not applicable
- Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in BangladeshCompletedNCT01122771Phase 3
- A Community Trial for Visceral Leishmaniasis (VL)CompletedNCT01069198Not applicable
- Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern AfricaCompletedNCT01067443Phase 2
- Efficacy of Topical Liposomal Form of Drugs in Cutaneous LeishmaniasisCompletedNCT01050777Early Phase 1
- Amphotericin B to Treat Visceral Leishmaniasis in Brazilian ChildrenCompletedNCT01032187Phase 4
- Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis PatientsCompletedNCT00996463Phase 2
- Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDLCompletedNCT00982774Phase 1
- Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous LeishmaniasisCompletedNCT00973128Phase 2
- To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala AzarCompletedNCT00876824Phase 3
- Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous LeishmaniasisStatus unknownNCT00840359Phase 2
- Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VLTerminatedNCT00832208Phase 2
- Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age PatientsCompletedNCT00818818Phase 4
- Frequency of Parasite Infection in Hyraxes and Sandflies During Outbreak of Leishmania Tropica Epidemic in The West BankStatus unknownNCT00737386
- Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral LeishmaniasisCompletedNCT00696969Phase 3
- Safety and Efficacy of Azithromycin to Treat Cutaneous LeishmaniasisTerminatedNCT00682656Phase 2/3
- An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral LeishmaniasisCompletedNCT00629031Phase 3
- Single Infusion of Liposomal Amphotericin B in Indian Visceral LeishmaniasisCompletedNCT00628719Phase 3
- Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral LeishmaniasisCompletedNCT00604955Phase 4
- Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)CompletedNCT00600548Phase 2
- Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in BoliviaStatus unknownNCT00537953Phase 2
- Combination Therapy in Indian Visceral LeishmaniasisCompletedNCT00523965Phase 3
- Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World LeishmaniasisNo longer availableNCT00508963
- A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-AzarCompletedNCT00497601Phase 2
- Cosmetic Outcome of Leishmaniasis Scar After WR279396 ApplicationCompletedNCT00490230Not applicable
- Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in ColombiaStatus unknownNCT00487253Phase 3
- Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in IndiaCompletedNCT00486382Phase 1
- Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and AllopurinolCompletedNCT00480883Not applicable
- Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous LeishmaniasisCompletedNCT00469495Not applicable
- Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia InfectionCompletedNCT00401557
- Expression of Mif Alleles in Individuals With LeishmaniasisCompletedNCT00401349
- Th1/Th2 Polarization and Linkage to L. Viannia Infection OutcomesCompletedNCT00401297
- A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis.CompletedNCT00381394Phase 2
- Miltefosine for Brazilian Visceral LeishmaniasisTerminatedNCT00378495Phase 1/2
- Miltefosine for Mucosal LeishmaniasisCompletedNCT00373776Phase 1/2
- Miltefosine (Long Course) for Bolivian Mucosal LeishmaniasisCompletedNCT00373568Phase 1/2
- Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azarCompletedNCT00371995Phase 2
- Combination Chemotherapy for the Treatment of Indian Kala-AzarCompletedNCT00370825Phase 2
- Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. TropicaCompletedNCT00351520Phase 3
- Surveillance for Leishmaniasis Skin Lesions in MaliCompletedNCT00344084
- Immunogenetics of Visceral LeishmaniasisCompletedNCT00342823
- Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala AzarCompletedNCT00318721Not applicable
- Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous LeishmaniasisCompletedNCT00317980Phase 4
- Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous LeishmaniasisTerminatedNCT00317629Phase 3
- Amphotericin B Treatment in Visceral LeishmaniasisCompletedNCT00310505Not applicable
- Imiquimod Plus Antimony Immunochemotherapy for Cutaneous LeishmaniasisCompletedNCT00257530Phase 3
- Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V LeishmaniasisCompletedNCT00255567Phase 3
- Miltefosine to Treat Cutaneous Leishmaniasis in BoliviaCompletedNCT00233545Phase 2
- Safety and Efficacy Study of Paromomycin to Treat Visceral LeishmaniasisCompletedNCT00216346Phase 3
- Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania ParasiteCompletedNCT00121862Phase 2
- Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania ParasiteCompletedNCT00121849Phase 1
- Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous LeishmaniasisCompletedNCT00111553Phase 1
- Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal LeishmaniasisCompletedNCT00111514Phase 1
- Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in BrazilCompletedNCT00004755Phase 2
- Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as AdjuvantsCompletedNCT00001906Phase 1
- Clinical Investigation of Infections Due to Leishmanial ParasitesCompletedNCT00001169